Notice of Proposed Sale · 144
Incyte Corp.
INCYNASDAQEQUITYCurrent
Notice of Proposed Sale
Structured filing — 144
primary_doc.xml
Notice of proposed sale. The proposed amounts below do not establish that a sale occurred.
Proposed-sale notice
- Issuer
- INCYTE CORPORATION
- Issuer CIK
- 0000879169
- SEC file number
- 001-12400
- Phone
- (302) 498-6700
- Person for whose account securities are to be sold
- STEVEN STEIN
- Relationships to issuer
- Officer
- Street
- 1801 Augustine Cut-Off
- City
- Wilmington
- State / country code
- DE
- Postal code
- 19803
Securities proposed for sale
| Security | Proposed units | Aggregate market value | Units outstanding | Approximate sale date | Exchange | Broker / market maker |
|---|---|---|---|---|---|---|
| Common | 1,877 | 215,339.39 | 199,782,155 | 07/16/2026 | NASDAQ | Morgan Stanley Smith Barney LLC Executive Financial Services |
Broker / market maker — proposed row 1, entry 1
- Name
- Morgan Stanley Smith Barney LLC Executive Financial Services
- Street
- 1 New York Plaza
- Street (continued)
- 8th Floor
- City
- New York
- State / country code
- NY
- Postal code
- 10004
Acquisition of securities to be sold
| Security | Acquired | Nature of acquisition | Acquired from | Amount acquired | Gift transaction | Payment date | Nature of payment |
|---|---|---|---|---|---|---|---|
| Common | 07/15/2026 | Restricted Stock | ISSUER | 1,877 | N | 07/15/2026 | Not Applicable |
Sales reported in the preceding three months
| Seller | Security | Sale date | Amount sold | Gross proceeds |
|---|---|---|---|---|
| STEVEN STEIN | Common | 07/15/2026 | 28,237 | 3,192,254.97 |
Seller — prior-sale row 1, entry 1
- Name
- STEVEN STEIN
- Street
- 1801 Augustine Cut-Off
- City
- Wilmington
- State / country code
- DE
- Postal code
- 19803
Prior-sale reporting
- Nothing to report for the preceding three months
- N
Notice signature
- Notice date
- 07/16/2026
- Signed
- /s/ Steven Stein
- Plan adoption dates
- 08/06/2025
Company context
Incyte is redefining what’s possible in biopharmaceutical innovation. Through deep scientific expertise and a relentless focus on patients, we have built an established portfolio of first-in-class medicines and an extensive portfolio of next-generation medicines across our key franchises: Hematology, Oncology and Inflammation and Autoimmunity. To learn more, visit Incyte.com and Investor. Incyte.com. Follow us on social media: LinkedIn, X and Instagram.